The world's first mRNA vaccine against a deadly disease

Published Date: 15 Mar 2023

A world first: A research team from Tel Aviv University and the Israel Institute of Biology has developed an anti-mRNA drug that is 100% effective against a single type of virus.

Read Full News

Latest News

Family History of Kidney Failure Tied to CKD Progression

In patients with chronic kidney disease, a family history of kidney failure may raise the risk for disease progression, even after accounting for individual genetic risk and social factors.

AI Finds Three Predictive Variants for Postoperative Sepsis

A genome-wide AI model prioritizes three genetic variants linked to postoperative sepsis and outlines how preoperative genotyping could support targeted monitoring strategies.

Are Italian Doctors Being Punished for Compassion?

The case of six Italian physicians accused of falsifying detention fitness certificates has ignited debate over science, conscience, and politics.

Managing Resistant Hypertension Is Like Playing Chess

Managing resistant hypertension requires looking two moves ahead. Dr Chuck Vega discusses edema, hypokalemia, and the surprising renal benefits of MRAs.

EU Panel Supports New Pediatric EoE Treatment

The CHMP has recommended approval of Jorveza oral suspension 0.2 mg/mL, the first licensed pediatric formulation of budesonide for eosinophilic esophagitis in the EU.

Does Budesonide Shield Against Air Pollution in Rhinitis?

In patients with allergic rhinitis, intranasal budesonide lowers type 2 and neutrophilic marker levels, improves airflow, and alters epigenetic age signals after allergen or diesel exhaust exposure.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Todays Updates

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Latest News

In patients with chronic kidney disease, a family history of kidney failure may raise the risk for disease progression, even after accounting for individual genetic risk and social factors.

A genome-wide AI model prioritizes three genetic variants linked to postoperative sepsis and outlines how preoperative genotyping could support targeted monitoring strategies.

The case of six Italian physicians accused of falsifying detention fitness certificates has ignited debate over science, conscience, and politics.

Managing resistant hypertension requires looking two moves ahead. Dr Chuck Vega discusses edema, hypokalemia, and the surprising renal benefits of MRAs.

The CHMP has recommended approval of Jorveza oral suspension 0.2 mg/mL, the first licensed pediatric formulation of budesonide for eosinophilic esophagitis in the EU.

In patients with allergic rhinitis, intranasal budesonide lowers type 2 and neutrophilic marker levels, improves airflow, and alters epigenetic age signals after allergen or diesel exhaust exposure.

News All Time

Vascular Cognitive Impairment and Dementia

This state of the art review describes the clinical features, pathophysiology, and biomarkers of vascular cognitive impairment and dementia for cardiovascular clinicians.

Impact of Environmental Allergens on Asthma Varies With Age

Older adults may be more vulnerable to asthma, study suggests.

Lymphoma Tx Linked to Mild Photodistributed Skin Reactions

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly photodistributed erythematous patches, a study finds.

EMA Supports First European Therapy for WHIM Syndrome

WHIM syndrome is an ultra-rare hereditary immunodeficiency disease that leads to recurrent severe infections and an increased risk for viral-associated cancer.

Study Backs Longer Compounded Lido Plus Epi Shelf Life

Research supports the safety and efficacy of compounded lidocaine plus epinephrine for up to 24 hours at room temperature and up to 7 days with refrigeration.

Two New Options for Chronic Spontaneous Urticaria in the EU

EU advisers recommend an oral add-on for adults who remain symptomatic on antihistamines and expanded dupilumab to ages 2-11, bringing the first biologic option to this group.

Secukinumab Doubles Remission Rate in Polymyalgia Rheumatica

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing polymyalgia rheumatica.

Store Peanut Products Effective for Desensitization in Kids?

A practical volume-based peanut oral immunotherapy protocol using store-bought peanut powder appears effective and safe for desensitizing children with peanut allergy.

Walk-In Visits Cut Wait Times for Children With AD, HS

Walk-in appointments can reduce the time to pediatric dermatology visits for both atopic dermatitis and hidradenitis suppurativa and reduce ED visits for atopic dermatitis, a study finds.

Measles Cases in South Carolina Rise by 6 to 979

Measles cases in South Carolina surged to 979 on Tuesday, state health data ⁠showed, including six additional infections since Friday.

Severe Infection Linked to Long-term IBD Risk

Severe infections requiring hospitalization are associated with a markedly increased long-term IBD risk, with immune-related genetic variants modifying susceptibility.

Study Reveals Gaps in ED Syphilis Screening

Despite increased STI testing in US emergency departments from 2020 to 2024, syphilis screening is often missed, particularly among female and insured patients.

Company Files for Approval of New Pustular Psoriasis Rx

Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.

Molluscum Rx: Recommendations From a Pediatric Dermatologist

Dr Swanson tells families that almost all kids get poxvirus-caused bumps and while treatment isn’t mandatory, options include topical cantharidin, berdazimer gel, and intralesional candida injections.

RSV Tamps Down Rhinovirus Coinfection in Infants

Order of infection appeared to affect disease severity in nasal tissue models.

Earlier Mepolizumab in EGPA May Raise Remission Rate

Initiating mepolizumab within 3 months of EGPA diagnosis is associated with a higher remission rate, earlier glucocorticoid withdrawal, and less damage accrual.

Recommended News For You

Bayer is transforming pharmaceutical research into women's health

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

More cancer cases in areas where incarceration rates are high: Study

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

Recommended Articles For You

Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis 

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment 

A Revolutionary Guide to Calculating Absolute Neutrophil Counts 

Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

2.

Bayer is transforming pharmaceutical research into women's health

3.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

4.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

5.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

1.

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities

2.

Decoding Efficacy, Safety, and Future Frontiers in CAR-T Cell Therapy for Hematologic Malignancies Towards CAR-T Therapy 2025

3.

Chondroma: What it is and How it Affects Your Health 

4.

Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer

5.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

2.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot